AI assistant
Sending…
EBOS GROUP LIMITED — Director's Dealing 2019
Sep 30, 2019
64813_rns_2019-09-30_a188a0eb-a3dd-48fc-92f3-9f76f7a89f74.pdf
Director's Dealing
Open in viewerOpens in your device viewer
==> picture [98 x 27] intentionally omitted <==
Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
| To NZX Limited; and | ||
|---|---|---|
| Name of listed issuer: | EBOS GroupLimited | |
| Date this disclosure made: | 1-Oct-19 | |
| Date of last disclosure: | 9-Apr-19 | |
| Director or senior manager giving disclosure | ||
Full name(s): |
Sean Duggan | |
| Name of listed issuer: | EBOS GroupLimited | |
| Name of related body corporate (if applicable): | N/A | |
| Position held in listed issuer: | CEO,Animal Care and Consumer Brands | |
| Summary of acquisition or disposal of relevant interest (excluding specified derivatives) Class ofaffected quotedfinancialproducts: Nature ofthe affectedrelevantinterest(s): For that relevant interest- Number held in class before acquisition or disposal: |
||
| Class ofaffected quotedfinancialproducts: | Ordinaryshares in EBOS GroupLimited | |
| Nature ofthe affectedrelevantinterest(s): | Sale of shares on-market | |
| For that relevant interest- | ||
| Number held in class before acquisition or disposal: | 45,000 ordinary shares (2016 long term incentiveplan shares) |
|
| Number held in class after acquisition or disposal: | Nil | |
| Current registered holder(s): | Sean Duggan | |
| Registeredholder(s) once transfers areregistered: | N/A | |
| Summary of acquisition or disposal of specified derivatives relevant interest (ifapplicab | le) | |
| Type of affected derivative: | N/A | |
| Class of underlyingfinancialproducts: | N/A | |
| Details of affected derivative- | ||
| The notional value of the derivative (if any) or the notional amount of underlying financial products(if any): |
N/A | |
| A statement as to whether the derivative is cash settled orphysicallysettled: | N/A | |
| Maturitydate of the derivative(if any): | N/A | |
| Expirydate of the derivative(if any): | N/A | |
| Theprice specified in the terms of the derivative(if any): | N/A | |
| Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlyingfinancialproducts: |
N/A | |
| _For that derivative,- _ | ||
| Parties to the derivative: | N/A | |
| If the director or senior manager is not a party to the derivative, the nature of the relevant interestinthe derivative: |
N/A | |
| Details of transactions giving rise to acquisition or disposal | ||
| Total numberoftransactions towhich noticerelates: | 1 | |
| 24-Sep-19 | ||
| Sale of shares on-market | ||
| N/A | ||
| $1,104,659.90. Under the 2016 long term incentive share plan the Company provided an interest-free, non-recourse loan to participating executives to purchase shares under the plan. Part of the proceeds from the sale of these shares will be used to satisfy in full the loan from the Companyto Mr Duggan. |
||
| 45,000 ordinaryshares |
| If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details— |
No N/A N/A Ordinaryshares 2.Registered holder - 2017 long term incentive plan 1. 310 ordinary shares 2. 50,000 ordinaryshares Sean Duggan N/A |
No N/A N/A Ordinaryshares 2.Registered holder - 2017 long term incentive plan 1. 310 ordinary shares 2. 50,000 ordinaryshares Sean Duggan N/A |
|
|---|---|---|---|
| Whether relevantinterestswere acquired ordisposed ofduring a closed period: | No | ||
| Whether prior written clearance was provided to allow the acquisition or disposal to proceed duringthe closedperiod: |
N/A | ||
| Date of theprior written clearance(if any): | N/A | ||
| Summary of other relevant interests after acquisition or disposal: | |||
| Class ofquoted financialproducts: | |||
| Nature of relevant interest: | |||
| _For that relevant interest,- _ | |||
| Number heldinclass: | |||
| Currentregisteredholder(s): | |||
| For a derivative relevant interest,- | |||
| Type ofderivative: | |||
| Details of derivative,- | |||
| The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): |
N/A | ||
| A statement as to whether the derivative is cash settled or physically settled: | N/A | ||
| Maturity date of the derivative (if any): | N/A | ||
| Expiry date of the derivative (if any): | N/A | ||
| The price's specified terms (if any): | N/A | ||
| Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlyingfinancialproducts: |
N/A | ||
| For that derivative relevant interest,- | N/A | ||
| Parties to the derivative: | N/A | ||
| If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative: |
N/A | ||
| Certification | 1-Oct-19 Janelle Cain, General Counsel, EBOS Group Limited |
||
| I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made. |
|||
| Signature of director or officer: | |||
| Date of signature: | |||
| or | |||
| Signature of person authorised to sign on behalf of director or officer: | |||
| Date of signature: | |||
| Name and title of authorised person: | |||
More from EBOS GROUP LIMITED
Share Issue/Capital Change
2026
May 18
Share Issue/Capital Change
2026
May 18
Share Issue/Capital Change
2026
May 17
Share Issue/Capital Change
2026
May 17
Share Issue/Capital Change
2026
May 17
Share Issue/Capital Change
2026
May 17
Capital/Financing Update
2026
May 6
Share Issue/Capital Change
2026
May 5
Capital/Financing Update
2026
May 5
Regulatory Filings
2026
May 1